Genetically engineered mouse models of pancreatic cancer.

Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov (2014) 1.97

GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech (2015) 0.92

Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts. PLoS One (2014) 0.85

Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Curr Protoc Pharmacol (2016) 0.75

Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. Oncotarget (2016) 0.75

miR-29a-deficiency does not modify the course of murine pancreatic acinar carcinoma. Oncotarget (2017) 0.75

No Functional Role for microRNA-342 in a Mouse Model of Pancreatic Acinar Carcinoma. Front Oncol (2017) 0.75

An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. Cancer Res (2017) 0.75

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21

Pancreatic cancer. N Engl J Med (2010) 13.88

Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development (2002) 12.21

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33

Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47

The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet (2002) 8.28

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36

Notch signalling controls pancreatic cell differentiation. Nature (1999) 7.18

Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet (2010) 6.81

Comparative biochemical properties of normal and activated human ras p21 protein. Nature (1984) 6.50

Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53

Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36

Biological and biochemical properties of human rasH genes mutated at codon 61. Cell (1986) 5.05

Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95

Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75

The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature (1984) 4.61

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov (2012) 4.30

Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28

GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev (2009) 4.21

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell (2012) 4.16

Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 4.12

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10

Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80

Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res (2008) 3.59

Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci U S A (2008) 3.40

Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23

Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev (2006) 3.16

Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15

Pancreas organogenesis: from bud to plexus to gland. Dev Dyn (2011) 3.14

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13

Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. Development (2011) 3.11

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest (2012) 2.95

Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest (2010) 2.90

Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res (1984) 2.74

Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54

Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell (2007) 2.36

Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21

The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A (2007) 2.18

BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science (2011) 2.17

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14

Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14

A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev (2001) 2.05

Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology (2011) 1.98

Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice. Dis Model Mech (2009) 1.97

Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol (2008) 1.96

Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell (2007) 1.86

Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene (2009) 1.85

Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2010) 1.84

Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.82

Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology (2008) 1.81

Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80

What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78

K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol (2008) 1.78

A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A (2008) 1.70

Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology (2011) 1.70

Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Res (2007) 1.66

PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res (2010) 1.65

Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest (2011) 1.58

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell (2010) 1.51

LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology (2010) 1.47

MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol (2008) 1.38

Animal transgenesis: an overview. Brain Struct Funct (2009) 1.29

Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol (2009) 1.23

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med (2012) 1.14

Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage. PLoS One (2011) 1.07

Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreas. Dev Biol (2011) 1.06

Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology (2011) 1.05

Dissecting the cellular origins of pancreatic cancer. Cell Cycle (2006) 1.02

Minireview: pancreatic progenitor cells--recent studies. Endocrinology (2008) 0.99

Somatic mutagenesis with a Sleeping Beauty transposon system leads to solid tumor formation in zebrafish. PLoS One (2011) 0.85

From tissue turnover to the cell of origin for pancreatic cancer. Nat Rev Gastroenterol Hepatol (2011) 0.85

Changes in connexin43 expression and localization during pancreatic cancer progression. J Membr Biol (2012) 0.82

RCAS-mediated retroviral gene delivery: a versatile tool for the study of gene function in a mouse model of pancreatic cancer. Hum Gene Ther (2008) 0.79

Lesions induced in rodent pancreas by azaserine and other pancreatic carcinogens. Environ Health Perspect (1984) 0.77

The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93

Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80

K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol (2008) 1.78

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell (2010) 1.51

Quantification of murine pancreatic tumors by high-resolution ultrasound. Methods Mol Biol (2013) 1.45

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res (2005) 1.26

A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. Cancer Chemother Pharmacol (2011) 1.15

Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11

Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model. Cancer Res (2009) 1.08

Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer. IEEE Trans Ultrason Ferroelectr Freq Control (2015) 0.79

Silencing the killers: paracrine immune suppression in pancreatic cancer. Cancer Cell (2012) 0.78

Recapitulating human cancer in a mouse. Nat Biotechnol (2013) 0.76

Acquisition of mouse tumor biopsies through abdominal laparotomy. Cold Spring Harb Protoc (2014) 0.76

Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI). Phys Med Biol (2016) 0.75